DDMODEL00000285: Executable_Laouenant_2015_CPTPSP_hb_RBV

  public model
Short description:
Model of RBV-induced anemia in Cirrhotic Hepatitis C Patients Treated With Triple Therapy
Original code
  • A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy
  • Laouénan C (1), Guedj J (2), Peytavin G (3), Nguyen TT (2), Lapalus M (4), Khelifa-Mouri F (5), Boyer N (5), Zoulim F (6), Serfaty L (7), Bronowicki JP (8), Martinot-Peignoux M (4), Lada O (4), Asselah T (9), Dorival C (10), Hézode C (11), Carrat F (12), Nicot F (13), Marcellin P (9), Mentré F (1)
  • CPT Pharmacometrics Syst. Pharmacol, 1/2015, Volume 4, pages: 37-40
  • (1) INSERM, IAME, UMR 1137, Univ Paris Diderot Sorbonne Paris Cité, Paris, France ; AP-HP, Hôpital Bichat, Departement of Biostatistic Paris, France. (2) INSERM, IAME, UMR 1137, Univ Paris Diderot Sorbonne Paris Cité, Paris, France. (3) INSERM, IAME, UM
  • Hezode et al. recently reported the frequent occurrence of anemia and thrombocytopenia in the ANRS-CO20-CUPIC cohort of hepatitis C virus (HCV) cirrhotic experienced patients treated with pegylated-interferon (Peg-IFN), ribavirin (RBV), and telaprevir or boceprevir.Using frequent measurements of serum drug concentrations, hemoglobin, and platelet concentrations obtained in 15 patients of this cohort, we show how an on-treatment model-based approach could be used to individualize dose regimen and avoid the occurrence of RBV-induced anemia and Peg-IFN-induced thrombocytopenia.
Julie Bertrand
Context of model development: Dose & Schedule Selection and Label Recommendation;
Model compliance with original publication: Yes;
Model implementation requiring submitter’s additional knowledge: No;
Modelling context description: Empirical Bayes estimates of individual values of ribavirin PK parameters (exponential model of trough concentrations at steady state) are used as regressors to link the concentration of ribavirin with the inhibition of hemoglobin synthesis (turnover model);
Modelling task in scope: estimation;
Nature of research: Clinical research & Therapeutic use;
Therapeutic/disease area: Anti-infectives;
Annotations are correct.
This model is not certified.
  • Model owner: Julie Bertrand
  • Submitted: May 16, 2018 8:59:28 AM
  • Last Modified: May 16, 2018 8:59:28 AM
Revisions
  • Version: 6 public model Download this version
    • Submitted on: May 16, 2018 8:59:28 AM
    • Submitted by: Julie Bertrand
    • With comment: Model revised without commit message
 
Help